{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:19:10Z","timestamp":1788279550473,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    In acute myeloid leukemia (AML), gaining chromosome 8 as the sole abnormality (sole +8) is rare. The prognostic impact and mutation profile of sole +8 AML remain unclear. We retrospectively analyzed a cohort of 75 patients with sole +8 AMLs who were diagnosed and treated at our institution. The genes most frequently harboring mutations in sole +8 AML were\n                    <jats:italic>ASXL1<\/jats:italic>\n                    (47%),\n                    <jats:italic>RUNX1<\/jats:italic>\n                    (32%),\n                    <jats:italic>SRSF2<\/jats:italic>\n                    (32%),\n                    <jats:italic>TET2<\/jats:italic>\n                    (27%),\n                    <jats:italic>DNM3A<\/jats:italic>\n                    (24%),\n                    <jats:italic>IDH2<\/jats:italic>\n                    (24%)\n                    <jats:italic>NRAS<\/jats:italic>\n                    (23%),\n                    <jats:italic>FLT3<\/jats:italic>\n                    (23%), and\n                    <jats:italic>STAG2<\/jats:italic>\n                    (23%). Age\u2010related differences in the genomic landscape were noted, characterized by a higher frequency of\n                    <jats:italic>ASXL1<\/jats:italic>\n                    ,\n                    <jats:italic>SRSF2<\/jats:italic>\n                    , and\n                    <jats:italic>TET2<\/jats:italic>\n                    mutations in older individuals with sole +8 AML. Sole +8 AML patients had a high frequency of myelodysplasia\u2010related (MR) gene mutations (74.2%). Survival of sole +8 AML patients was inferior compared to European LeukemiaNet (ELN) 2022 intermediate\u2010risk patients (median OS: 14.6\u00a0months vs. not reached: NR,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.013), but similar to ELN adverse risk patients (median OS: 16.2,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.72). Categorizing patients on the basis of MR gene mutations revealed that the inferior survival of sole +8 patients may be attributed to the high frequency of MR gene mutations in these patients. These findings indicate the importance of genetic mutations, specifically MR genes, in sole +8 AML.\n                  <\/jats:p>","DOI":"10.1002\/hon.70207","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T10:51:15Z","timestamp":1780743075000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mutational Landscape and Clinical Outcomes in AML With Sole Trisomy 8"],"prefix":"10.1002","volume":"44","author":[{"given":"Ehsan","family":"Bahrami Hezaveh","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology University of Toronto  Toronto Ontario Canada"},{"name":"Department of Laboratory Hematology Laboratory Medicine Program University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Anthony","family":"Turingan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology University of Toronto  Toronto Ontario Canada"},{"name":"Department of Laboratory Hematology Laboratory Medicine Program University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianghua","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology University of Toronto  Toronto Ontario Canada"},{"name":"Department of Laboratory Hematology Laboratory Medicine Program University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihong","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Genetics, Genome Diagnostics &amp; Cancer Cytogenetics University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tierens","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology University of Toronto  Toronto Ontario Canada"},{"name":"Department of Laboratory Hematology Laboratory Medicine Program University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Sibai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Cancer Centre University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology University of Toronto  Toronto Ontario Canada"},{"name":"Department of Laboratory Hematology Laboratory Medicine Program University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1406184"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.patbio.2006.04.007"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14434"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1657400"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12861"},{"issue":"5","key":"e_1_2_12_7_1","first-page":"1235","article-title":"Patients With Isolated Trisomy 8 in Acute Myeloid Leukemia Are Not Cured With Cytarabine\u2010Based Chemotherapy: Results From Cancer and Leukemia Group B 8461","volume":"4","author":"Byrd J. C.","year":"1998","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyq097"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001613\u20101"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.114"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2071799"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/isbn.978-3-318-05979-3"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010021\u201001255\u20104"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018021469"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517\u20106161.1995.tb02031.x"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010023\u201002016\u20106"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010025\u201002622\u20106"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.11.026"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290012074"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102002\u201003\u20100772"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010025\u201001332\u20107"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19249"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.21.5.1041"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.051532"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.326"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010025\u201002781\u20106"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13979"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011173"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17040667"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010198"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1179296"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70207","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.70207","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:36:26Z","timestamp":1788276986000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/hon.70207"],"URL":"https:\/\/doi.org\/10.1002\/hon.70207","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"2026-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70207"}}